-
公开(公告)号：US20110125089A1
公开(公告)日：2011-05-26
申请号：US12935114
申请日：2009-03-26
申请人： Richard I. Senderoff , Jeffrey D. Meyer , Emily N. Rollins , Steven D. Hughes , Richard M. Garcoa , Paul D. Bishop , Gerald W. Lasser
发明人： Richard I. Senderoff , Jeffrey D. Meyer , Emily N. Rollins , Steven D. Hughes , Richard M. Garcoa , Paul D. Bishop , Gerald W. Lasser
CPC分类号： A61K47/42 , A61K9/0024 , A61K9/06 , A61K38/4833 , A61K47/10 , A61K47/26 , A61K47/32 , A61K47/38 , C12Y304/21005 , Y10T428/2982
摘要： Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
摘要翻译： 本文提供止血组合物。 在一个实施方案中，止血组合物包括交联聚合物微球体，例如具有孔的交联明胶微球体。 在另一个实施方案中，止血组合物包含添加剂，例如润湿剂，悬浮剂或两者。 止血组合物还可以包括止血剂如凝血酶，并且可以包括高浓度的凝血酶。 止血组合物还可以包括血浆。 本文还提供了用于将所述止血组合物分散在稀释剂中并递送所述分散的止血组合物的装置。 止血组合物也可以按照给药方式制备具有所选择的几何形状。
-
公开(公告)号：US09629798B2
公开(公告)日：2017-04-25
申请号：US12935114
申请日：2009-03-26
申请人： Richard I. Senderoff , Jeffrey D. Meyer , Emily N. Rollins , Steven D. Hughes , Richard M. Garcia , Paul D. Bishop , Gerald W. Lasser
发明人： Richard I. Senderoff , Jeffrey D. Meyer , Emily N. Rollins , Steven D. Hughes , Richard M. Garcia , Paul D. Bishop , Gerald W. Lasser
CPC分类号： A61K47/42 , A61K9/0024 , A61K9/06 , A61K38/4833 , A61K47/10 , A61K47/26 , A61K47/32 , A61K47/38 , C12Y304/21005 , Y10T428/2982
摘要： Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
-
公开(公告)号：US20100316599A1
公开(公告)日：2010-12-16
申请号：US12768970
申请日：2010-04-28
CPC分类号： C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要： Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
-
公开(公告)号：US07265203B2
公开(公告)日：2007-09-04
申请号：US10968432
申请日：2004-10-19
申请人： Scott R. Presnell , Wenfeng Xu , Wayne Kindsvogel , Zhi Chen , Steven D. Hughes
发明人： Scott R. Presnell , Wenfeng Xu , Wayne Kindsvogel , Zhi Chen , Steven D. Hughes
IPC分类号： C07K14/52
CPC分类号： C07K14/715 , A61K38/00
摘要： Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”
摘要翻译： 细胞因子及其受体已被证明在基础研究和治疗方面都是有用的。 本发明提供了称为“Zcytor16”的新的人细胞因子受体。
-
公开(公告)号：US20110002882A1
公开(公告)日：2011-01-06
申请号：US12762771
申请日：2010-04-19
CPC分类号： C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要： Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
摘要翻译： 描述了使用具有IL-21功能活性的分子治疗具有癌症的哺乳动物的方法。 具有IL-21功能活性的分子包括与人IL-21多肽序列具有同源性的多肽和与具有IL-21功能活性的多肽融合的蛋白质。 分子可以用作单一疗法或与其他已知的癌症治疗剂组合使用。
-
公开(公告)号：US07718172B2
公开(公告)日：2010-05-18
申请号：US11829765
申请日：2007-07-27
IPC分类号： A61K39/395 , C07K14/54 , C07K16/00 , C07K16/22
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/34
摘要： The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
摘要翻译： 本发明涉及阻断IL-TIF多肽分子的活性。 IL-TIF是涉及炎症过程和人类疾病的细胞因子。 本发明包括抗IL-TIF抗体和结合配偶体，以及在IL-TIF相关的人类炎性疾病中使用这样的抗体和结合伴侣拮抗IL-TIF的方法，以及其它用途。
-
公开(公告)号：US20090087404A1
公开(公告)日：2009-04-02
申请号：US12250911
申请日：2008-10-14
申请人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
发明人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
CPC分类号： C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
摘要： Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
-
公开(公告)号：US20090022723A1
公开(公告)日：2009-01-22
申请号：US11829765
申请日：2007-07-27
IPC分类号： A61K39/395 , C12N5/06 , A61P29/00
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/34
摘要： The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
摘要翻译： 本发明涉及阻断IL-TIF多肽分子的活性。 IL-TIF是涉及炎症过程和人类疾病的细胞因子。 本发明包括抗IL-TIF抗体和结合配偶体，以及在IL-TIF相关的人类炎性疾病中使用这样的抗体和结合伴侣拮抗IL-TIF的方法，以及其它用途。
-
公开(公告)号：US08101381B2
公开(公告)日：2012-01-24
申请号：US12832882
申请日：2010-07-08
申请人： Scott R. Presnell , Wenfeng Xu , Wayne Kindsvogel , Zhi Chen , Steven D. Hughes
发明人： Scott R. Presnell , Wenfeng Xu , Wayne Kindsvogel , Zhi Chen , Steven D. Hughes
CPC分类号： C07K14/715 , A61K38/00
摘要： Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides polynucleotides, vectors, cells, and methods of production related to a new human cytokine receptor designated as “Zcytor16.”
摘要翻译： 细胞因子及其受体已被证明在基础研究和治疗方面都是有用的。 本发明提供与称为“Zcytor16”的新的人类细胞因子受体相关的多核苷酸，载体，细胞和生产方法。
-
公开(公告)号：US20100322898A1
公开(公告)日：2010-12-23
申请号：US12771667
申请日：2010-04-30
CPC分类号： C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要： Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.05 秒)
